MA34658B1 - Dérivés d'hétéroarylsulfonamides, leur préparation et leur application en thérapie humaine - Google Patents

Dérivés d'hétéroarylsulfonamides, leur préparation et leur application en thérapie humaine

Info

Publication number
MA34658B1
MA34658B1 MA35892A MA35892A MA34658B1 MA 34658 B1 MA34658 B1 MA 34658B1 MA 35892 A MA35892 A MA 35892A MA 35892 A MA35892 A MA 35892A MA 34658 B1 MA34658 B1 MA 34658B1
Authority
MA
Morocco
Prior art keywords
group
atom
cellarized
linear
derivatives
Prior art date
Application number
MA35892A
Other languages
English (en)
French (fr)
Inventor
Elisabeth Dupont-Passelaigue
Roy Isabelle Le
Christophe Pignier
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA34658B1 publication Critical patent/MA34658B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA35892A 2010-11-23 2013-05-13 Dérivés d'hétéroarylsulfonamides, leur préparation et leur application en thérapie humaine MA34658B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1059634A FR2967674B1 (fr) 2010-11-23 2010-11-23 Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
PCT/EP2011/070736 WO2012069503A1 (en) 2010-11-23 2011-11-23 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy

Publications (1)

Publication Number Publication Date
MA34658B1 true MA34658B1 (fr) 2013-11-02

Family

ID=44246390

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35892A MA34658B1 (fr) 2010-11-23 2013-05-13 Dérivés d'hétéroarylsulfonamides, leur préparation et leur application en thérapie humaine

Country Status (19)

Country Link
US (2) US8846930B2 (enExample)
EP (1) EP2643318A1 (enExample)
JP (1) JP5837085B2 (enExample)
KR (1) KR101838326B1 (enExample)
CN (1) CN103209980B (enExample)
AR (1) AR083903A1 (enExample)
AU (1) AU2011333772B2 (enExample)
BR (1) BR112013012615A2 (enExample)
CA (1) CA2817531A1 (enExample)
FR (1) FR2967674B1 (enExample)
IL (1) IL226495A (enExample)
MA (1) MA34658B1 (enExample)
MX (1) MX352396B (enExample)
MY (1) MY168283A (enExample)
NZ (1) NZ610700A (enExample)
RU (1) RU2582995C2 (enExample)
TW (1) TWI576106B (enExample)
UA (1) UA109295C2 (enExample)
WO (1) WO2012069503A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
EP2704720B1 (en) * 2011-05-03 2019-08-07 Agios Pharmaceuticals, Inc. Pyruvate kinase r activators for use in therapy
PT3406251T (pt) 2011-05-03 2024-01-24 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015055447A1 (en) * 2013-10-17 2015-04-23 Basf Se Process for preparing substituted isatoic acid anhydride compounds and derivatives thereof
WO2015095111A1 (en) * 2013-12-18 2015-06-25 Merck Sharp & Dohme Corp. Diazepane orexin receptor antagonists
CN104292179A (zh) * 2014-10-19 2015-01-21 湖南华腾制药有限公司 一种2-氯苯并[d]恶唑-5-甲醛的制备方法
FR3029112A1 (fr) * 2014-12-02 2016-06-03 Pf Medicament Dispersion solide a base de derives d'heteroarylsulfonamides a usage pharmaceutique
MX384883B (es) 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.
EP3601273B1 (en) * 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
CN107556266B (zh) * 2017-09-12 2021-04-23 华南农业大学 一种2-巯基-4-取代-6-氟苯并噻唑及其制法、应用
US20200131156A1 (en) * 2018-10-30 2020-04-30 H. Lundbeck A/S ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS
CN113200934B (zh) * 2021-05-18 2022-05-31 郑州大学 含苯并吗啉酮-联苯骨架化合物及其制备方法和应用
CN113912595B (zh) * 2021-10-12 2024-03-15 中国药科大学 一类含有噻唑或噻二唑结构的化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149700A (en) * 1990-05-30 1992-09-22 American Home Products Corporation Substituted arylsulfonamides and benzamides
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
PL1828154T3 (pl) * 2004-12-09 2009-10-30 Hoffmann La Roche Pochodne fenylopiperazynometanonu
EP1902051A1 (en) * 2005-06-09 2008-03-26 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CN101296914B (zh) * 2005-08-26 2012-07-18 盐野义制药株式会社 具有ppar激动活性的衍生物
CA2702772A1 (en) * 2007-10-25 2009-04-30 Boehringer Ingelheim International Gmbh Diazepane compounds which modulate the cb2 receptor
CA2727780A1 (en) * 2008-06-13 2009-12-17 Bionomics Limited Novel potassium channel blockers and uses thereof
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
CN101503392B (zh) * 2009-03-31 2010-12-29 中国药科大学 芳甲胺类化合物、其制备方法及其医药用途
WO2010130638A1 (en) * 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
PE20120693A1 (es) * 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)

Also Published As

Publication number Publication date
KR101838326B1 (ko) 2018-03-13
NZ610700A (en) 2014-12-24
HK1187345A1 (en) 2014-04-04
IL226495A0 (en) 2013-07-31
BR112013012615A2 (pt) 2016-09-06
MX2013005734A (es) 2013-08-01
US8846930B2 (en) 2014-09-30
AR083903A1 (es) 2013-04-10
CA2817531A1 (en) 2012-05-31
FR2967674B1 (fr) 2012-12-14
UA109295C2 (uk) 2015-08-10
CN103209980B (zh) 2015-06-03
CN103209980A (zh) 2013-07-17
RU2582995C2 (ru) 2016-04-27
AU2011333772A1 (en) 2013-06-06
US20140357624A1 (en) 2014-12-04
RU2013126251A (ru) 2014-12-27
TW201225951A (en) 2012-07-01
US20130172326A1 (en) 2013-07-04
US9156834B2 (en) 2015-10-13
IL226495A (en) 2017-06-29
AU2011333772B2 (en) 2016-08-18
EP2643318A1 (en) 2013-10-02
KR20130119943A (ko) 2013-11-01
MX352396B (es) 2017-11-22
FR2967674A1 (fr) 2012-05-25
JP5837085B2 (ja) 2015-12-24
WO2012069503A1 (en) 2012-05-31
JP2014502268A (ja) 2014-01-30
MY168283A (en) 2018-10-19
TWI576106B (zh) 2017-04-01

Similar Documents

Publication Publication Date Title
MA26996A1 (fr) Derives de glutaramide a substituant n-phenpropylcyclopentyle, servant d'inhibiteurs de nep pour un trouble d'eveil sexuel feminin
MA31319B1 (fr) Dérivés de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MX352396B (es) Derivados de heteroarilsulfonamidas, su preparacion y su aplicacion en terapia humana.
CA2662848C (fr) Derives de 2-aryl-6-phenyl-imidazo[1,2-.alpha.]pyridines, leur preparation et leur application en therapeutique
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
MA30162B1 (fr) Nouveaux derives de pyrrole a cycles fusionnes
EA200602260A1 (ru) Применение замещенных хинолиновых производных для лечения заболеваний, вызываемых микобактериями, резистентными к лекарственным средствам
SE0104334D0 (sv) Therapeutic agents
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
MA31800B1 (fr) Dérivés de tétrahydroquinoléine pour traiter des troubles de stress post-traumatique
IN2014CN00532A (enExample)
TNSN06439A1 (fr) Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique
DK1653943T3 (da) Catecholderivater til behandling af cancer
HUP9700574A2 (hu) N,N-Dimetil-(3-fenil-but-3-én)-amin-származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
RU2012155118A (ru) Способы лечения биполярного расстройства
MA27390A1 (fr) Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
EE200000504A (et) Bensofurüül-a-pürooni derivaadid, farmatseutilinekompositsioon, lipiidide ainevahetuse kiirendaja,triglütseriidi biosünteesi inhibiitor, vere triglütseriiditaset alandav toimeaine, vere HDL taset tõstev toimeaine, arterioskleroosi profülaktiline to
MA31674B1 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique
NO20070605L (no) Nye 2-substituerte D-homoostra-1,3,5(10)-triener som inhibitor av 17(3-hydroksysteroiddehydrogenaser type-1.
MX2009013581A (es) Derivados de 4-(n-azacicloalquil)anilidas como moduladores del canal de potasio.
TN2010000025A1 (fr) Derives de l'indol -2-one disubstitues en 3, leur preparation et leur application en therapeutique
CA2434063A1 (fr) Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus
MA29343B1 (fr) Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
DK0458551T3 (da) Spiro-isoquinolin-pyrrolidiner og analoge deraf, som er anvendelige som aldosereduktase-inhibitorer.
BR0011127A (pt) Derivados de 4-fenil-pirimidina